Short Interest in enVVeno Medical Corporation (NASDAQ:NVNO) Drops By 16.0%

enVVeno Medical Corporation (NASDAQ:NVNO) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 447,400 shares, a decrease of 16.0% from the February 28th total of 532,700 shares. Based on an average daily volume of 127,600 shares, the days-to-cover ratio is currently 3.5 days. Approximately 2.6% of the shares of the company are sold short.

Hedge Funds Weigh In On enVVeno Medical

A number of hedge funds and other institutional investors have recently modified their holdings of NVNO. Maven Securities LTD bought a new position in shares of enVVeno Medical in the 3rd quarter worth approximately $295,000. Geode Capital Management LLC lifted its stake in shares of enVVeno Medical by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after buying an additional 10,902 shares in the last quarter. Hohimer Wealth Management LLC purchased a new position in shares of enVVeno Medical in the third quarter worth $286,000. Westside Investment Management Inc. increased its stake in enVVeno Medical by 128.0% in the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. Finally, Fermata Advisors LLC grew its position in enVVeno Medical by 18.1% in the fourth quarter. Fermata Advisors LLC now owns 35,706 shares of the company’s stock worth $108,000 after acquiring an additional 5,481 shares in the last quarter. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

enVVeno Medical Trading Down 4.2 %

enVVeno Medical stock traded down $0.11 during trading hours on Tuesday, reaching $2.52. 78,706 shares of the stock were exchanged, compared to its average volume of 107,480. The stock has a 50 day moving average of $3.17 and a two-hundred day moving average of $3.31. The company has a market cap of $44.19 million, a P/E ratio of -1.96 and a beta of 1.38. enVVeno Medical has a twelve month low of $2.45 and a twelve month high of $6.48.

enVVeno Medical (NASDAQ:NVNO) last issued its earnings results on Thursday, February 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. On average, analysts expect that enVVeno Medical will post -1.32 earnings per share for the current fiscal year.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).